Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

The announcement by Health Secretary Wes Streeting that the NHS Jewish BRCA Testing Programme is to be restarted next year is welcome news. Most importantly, it will come as a great relief for anyone ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — More than one-third of U.S. adults diagnosed with metastatic HER2-negative breast cancer in 2023 ...

In a cover story for the first issue of TIME France, Angelina Jolie unveiled her double mastectomy surgircal scars over 10 years after she had the procedure, and explained why she decided to share ...

Cedars Sinai gets 30M to establish a specialized BRCA cancer center focusing on research, diagnosis, and treatment in Los Angeles.

A pioneering study has found that an individualized approach to breast cancer screening that assesses patients' risk, rather ...

Angelina Jolie has spent decades redefining what it means to be powerful in Hollywood. This week, she added another chapter to that legacy. For the first time, the “Maria” star has chosen to publicly ...

Angelina Jolie has revealed her mastectomy scars after 12 years (Picture: Andrea Staccioli/Insidefoto/Mondadori Portfolio via Getty Images) Angelina Jolie has shown her mastectomy scars for the first ...

At the San Antonio Breast Cancer Symposium, investigators from an international consortium reported that knowledge of BRCA1/2 mutation status strongly influenced surgical decision-making in young ...

Johnson & Johnson’s sNDA for Akeega gets US FDA approval to treat patients with BRCA2-mutated mCSPC: Horsham, Pennsylvania Wednesday, December 17, 2025, 13:00 Hrs [IST] Johnson ...